iBio, Inc. 8-K

What Happened

• On July 1, 2026 iBio, Inc. (IBIO) filed a Form 8-K (Items 7.01 and 8.01) and issued a press release reporting new preclinical results from an obese non-human primate (NHP) study of IBIO-610, a potential first‑in‑class Activin E antibody candidate.
• Following a single dose, active Activin E in treated NHPs was reduced in all animals and remained suppressed through eight weeks; active Activin E was reduced to below assay limits at weeks 4 and 8 and was reduced by 98% at week 4 and 97% at week 8 versus baseline.

Key Details

• Study model: obese non‑human primates (NHPs); single dose of IBIO-610.
• Activin E suppression: 98% reduction at week 4, 97% at week 8; levels below assay limits at weeks 4 and 8.
• Combination data: when combined with semaglutide, IBIO-610 produced greater visceral and total fat loss and reduced lean mass loss by 73% versus semaglutide alone.
• Next disclosure: the full data will be presented at the 62nd Annual Meeting of the European Association for the Study of Diabetes (EASD), Sept 28–Oct 2, 2026 in Milan, Italy.

Why It Matters

• These preclinical results support iBio’s claims that IBIO-610 can strongly inhibit the Activin E pathway for an extended period after a single dose, suggesting potential for infrequent dosing and a long-acting antibody approach.
• The fat‑selective weight loss and reduced lean mass loss when combined with semaglutide highlight IBIO-610’s possible role as both a stand‑alone obesity therapy and a complementary treatment to GLP‑1–based drugs, which is relevant to the company’s clinical development strategy and investor interest.
• Investors should note this is preclinical NHP data; the company plans to present full data at EASD, which may provide more detail and drive further news flow.